The Infectious Diseases Society of America (IDSA) has established multidisciplinary guidelines to review the available data and formulate recommendations regarding the care and management of COVID-19 patients. This guideline panel has made 32 recommendations for treating and managing the following populations: before and after exposure prophylaxis, ambulatory patients with mild to moderate disease, hospitalized with mild to moderate disease, severe but not critical disease, and critical disease. We are publishing a series of posts to cover these guidelines.
Here’s the latest addition to the list of IDSA recommendations on neutralizing antibodies! Guidelines on the usage of Neutralizing Antibodies/Neutralizing Monoclonal Antibodies (nAbs) in COVID-19 treatment Neutralizing Antibodies & Benefits These monoclonal antibodies target the receptor-binding domain of SARS-CoV-2 spike protein and…
